By InvitationPhase 2

A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

United States372 participantsStarted 2026-01-26

Plain-language summary

This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503. * Other, more specific inclusion criteria are defined in the protocol. Exclusion Criteria: * Have permanently discontinued IMP during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study.

What they're measuring

Percentage of Group A Participants who remain euthyroid, Off ATD, and Off IMVT-1402

Timeframe: At Week 52

Trial details

NCT IDNCT07286006

SponsorImmunovant Sciences GmbH

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2030-03

View on ClinicalTrials.gov More Graves' Disease trials